This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Activity Details
328 * | Tue, 8/3/2010, 10:30 AM - 12:20 PM | CC-215 (West) |
Meta-Analysis Related to Regulatory Issues: The FDA Guidance Document for Diabetes and Cardiovascular Risk — Topic Contributed Papers | ||
Biopharmaceutical Section , ENAR , Health Policy Statistics Section | ||
Organizer(s): Joan Buenconsejo, FDA | ||
Chair(s): Andreas Brueckner, Bayer Schering Pharma | ||
10:35 AM | Evaluating Cardiovascular Risk in Diabetes Clinical Trials: Lessons Learned from Saxagliptin — J Mark Donovan, Bristol-Myers Squibb | |
10:55 AM | Multiplicity Issues in Meta-Analyses to Rule Out an Unacceptable Cardiovascular Risk — Stefan Hantel, Boehringer Ingelheim Pharmaceuticals, Inc. | |
11:15 AM | Evaluating Cardiovascular Risk in Diabetes Clinical Trials: An FDA Statistician's Perspective — Jon Todd Sahlroot, FDA | |
11:35 AM | Micro-Macro; FDA-EMA: On Developing Diabetes Drugs — Janet Wittes, Statistics Collaborative, Inc. | |
11:55 AM | Discussant: Steve Snappin, Amgen Inc. | |
12:15 PM | Floor Discussion |
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.